PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for CNN Neumología

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More CONACEM Medical Specialty Board Certification Examinations (Mexico)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Consejo Mexicano de Certificación en Pediatría — Certificación en Pediatría (Mexico)

Practice Questions

Consejo Mexicano de Medicina de Urgencias — Certificación en Medicina de Urgencias (Mexico)

Practice Questions

Consejo Mexicano de Psiquiatría — Certificación en Psiquiatría (Mexico)

Practice Questions

Consejo Mexicano de Radiología e Imagen — Certificación en Radiología e Imagen (Mexico)

Practice Questions

Consejo Mexicano de Cirugía General — Certificación en Cirugía General (Mexico)

Practice Questions

Consejo Mexicano de Dermatología — Certificación en Dermatología (Mexico)

Practice Questions
Exam Review

Key Facts: CNN Neumología Exam

6 Feb 2027

Exam date (digital, own laptop)

CNN convocatoria 2026-2027

15 Sep-15 Dec 2026

Registration window (no extension)

CNN convocatoria 2026-2027

MXN 6,000

Registration fee

CNN convocatoria 2026-2027

CDMX, MTY, GDL

Regional exam sites

CNN convocatoria 2026-2027

19 Feb 2027

Results communicated by

CNN convocatoria 2026-2027

The CNN certification is the CONACEM-recognized board exam for adult pulmonology in Mexico: a digital exam on the candidate's own laptop on 6 February 2027 in Mexico City, Monterrey or Guadalajara. Registration runs 15 September-15 December 2026 and the fee is MXN 6,000.

Sample CNN Neumología Practice Questions

Try these sample questions to review concepts for the CNN Neumología exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 58-year-old male with a 35 pack-year smoking history presents with progressive exertional dyspnea and chronic morning cough. Pre-bronchodilator spirometry shows FEV1 of 1.80 L (52% predicted) and FVC of 3.10 L (74% predicted), yielding an FEV1/FVC ratio of 0.58. Following administration of 400 mcg of inhaled albuterol, his FEV1 increases to 1.95 L (an 8.3% and 150 mL increase), and FVC increases to 3.25 L, with a post-bronchodilator FEV1/FVC ratio of 0.60. According to GOLD guidelines, which criterion establishes the definitive diagnosis of persistent airflow limitation?
A.A post-bronchodilator FEV1/FVC ratio less than 0.70
B.An increase in FEV1 less than 12% and 200 mL following bronchodilator inhalation
C.A pre-bronchodilator FEV1 less than 80% of predicted normal value
D.A post-bronchodilator forced vital capacity (FVC) less than 80% predicted
Explanation: The global GOLD consensus defines chronic obstructive pulmonary disease (COPD) by the presence of non-fully reversible airflow limitation demonstrated by a post-bronchodilator FEV1/FVC ratio < 0.70 (or below the lower limit of normal, LLN). While bronchodilator reversibility testing is standard, the fixed post-bronchodilator ratio < 0.70 remains the required threshold for diagnosing persistent obstruction.
2A 66-year-old female with confirmed COPD (post-bronchodilator FEV1 48% predicted) presents for routine evaluation. Over the preceding 12 months, she experienced one severe exacerbation requiring hospital admission and three days of systemic corticosteroids, as well as one moderate outpatient exacerbation treated with oral antibiotics. Her mMRC dyspnea score is 1, and her COPD Assessment Test (CAT) score is 8. According to the updated GOLD 2024/2026 assessment framework, into which management group should this patient be categorized?
A.Group A
B.Group E
C.Group B
D.Group D
Explanation: In the updated GOLD assessment scheme, Groups C and D were consolidated into Group E (Exacerbations). Any patient who has experienced two or more moderate exacerbations or at least one exacerbation leading to hospital admission within the past year is classified into Group E, regardless of baseline symptom burden (mMRC or CAT score).
3A 64-year-old male with severe COPD (FEV1 42% predicted) remains persistently breathless and suffered two moderate exacerbations over the past 8 months despite adherent dual bronchodilator therapy with tiotropium and olodaterol (LAMA/LABA). His complete blood count reveals a peripheral blood eosinophil count of 380 cells/uL (4.2%). He has no history of mycobacterial disease or recurrent pneumonia. What is the most appropriate next step in his pharmacological management?
A.Add oral roflumilast 500 mcg once daily to dual bronchodilator therapy
B.Switch tiotropium/olodaterol to an inhaled corticosteroid/LABA combination
C.Step up to single-inhaler triple therapy by adding an inhaled corticosteroid (ICS/LABA/LAMA)
D.Initiate long-term azithromycin maintenance therapy at 250 mg three times weekly
Explanation: Per GOLD recommendations, patients experiencing recurrent exacerbations on dual LAMA/LABA maintenance therapy who have a blood eosinophil count >= 300 cells/uL derive significant clinical benefit from the addition of an inhaled corticosteroid, escalating to single-inhaler triple therapy (ICS/LABA/LAMA). High eosinophil counts predict a favorable prevention response against future exacerbations.
4A 61-year-old man presents with chronic breathlessness on climbing inclines (mMRC score 2, CAT score 16). He has not experienced any exacerbations in the preceding year. Spirometry confirms airflow obstruction with post-bronchodilator FEV1 62% predicted. He is diagnosed with GOLD Group B COPD. What is the guideline-recommended initial maintenance pharmacological therapy?
A.Short-acting beta-2 agonist (SABA) as-needed monotherapy
B.Inhaled corticosteroid plus long-acting beta-2 agonist (ICS/LABA)
C.Long-acting muscarinic antagonist (LAMA) monotherapy
D.Combination long-acting beta-2 agonist plus long-acting muscarinic antagonist (LABA/LAMA)
Explanation: GOLD guidelines recommend upfront dual bronchodilator therapy with a LABA plus a LAMA as the preferred initial maintenance regimen for patients in Group B (symptomatic, low exacerbation risk), as dual bronchodilation provides superior improvements in FEV1, dyspnea scores, and health status compared to monotherapy.
5A 67-year-old male with known COPD presents to the outpatient clinic with a 3-day history of increased sputum volume, sputum purulence, and worsened baseline dyspnea (Anthonisen Type 1 exacerbation). He is hemodynamically stable without signs of respiratory failure. In addition to short-acting bronchodilators and an appropriate oral antibiotic, which systemic corticosteroid regimen is recommended by GOLD guidelines?
A.Oral dexamethasone 8 mg daily for 14 days followed by a 2-week taper
B.Oral prednisone 40 mg daily for 5 days without an extended taper
C.Intravenous methylprednisolone 125 mg every 6 hours for 7 days
D.Oral prednisone 60 mg daily for 14 days with an abrupt cessation
Explanation: GOLD guidelines recommend oral prednisone 40 mg daily for 5 days for acute COPD exacerbations. Clinical trials (such as the REDUCE trial) confirmed that a 5-day course of systemic corticosteroids is non-inferior to a 14-day course in terms of re-exacerbation rates and lung function recovery, while significantly reducing glucocorticoid-related adverse events.
6A 70-year-old male with advanced COPD (FEV1 31% predicted) is evaluated in a stable clinical state 3 months after an exacerbation. Arterial blood gas on ambient air at sea level shows pH 7.39, PaCO2 44 mmHg, and PaO2 53 mmHg (resting SaO2 87%). An echocardiogram reveals normal left ventricular function and an estimated pulmonary artery systolic pressure of 32 mmHg. What is the evidence-based recommendation regarding long-term oxygen therapy (LTOT)?
A.LTOT is indicated only if nocturnal polysomnography demonstrates hypopnea index > 15
B.LTOT is not indicated unless PaO2 falls below 50 mmHg on repeat blood gas testing
C.Prescribe continuous LTOT for at least 15 hours per day to improve survival
D.Prescribe ambulatory oxygen therapy strictly for exertion, without nocturnal administration
Explanation: Evidence from landmark trials (MRC and NOTT) establishes that long-term continuous oxygen therapy (>= 15 hours/day, including sleeping hours) improves survival in patients with severe chronic resting hypoxemia, defined as resting PaO2 <= 55 mmHg (or SaO2 <= 88%) on ambient air in a clinically stable state.
7A 63-year-old female with severe COPD is admitted to the emergency department with acute respiratory distress, tachypnea (34 breaths/min), and accessory muscle use. Arterial blood gas on 2 L/min nasal cannula reveals: pH 7.28, PaCO2 62 mmHg, PaO2 58 mmHg, and HCO3 28 mEq/L. She is alert, cooperative, and able to clear secretions. What is the first-line ventilatory support strategy?
A.Immediate endotracheal intubation and invasive mechanical ventilation
B.High-flow nasal cannula (HFNC) set at 60 L/min and FiO2 0.60
C.Venturi mask delivering 40% oxygen without positive pressure support
D.Non-invasive positive pressure ventilation (NIV / bilevel positive airway pressure)
Explanation: Non-invasive positive pressure ventilation (NIV/BiPAP) is the first-line intervention in acute hypercapnic respiratory failure complicating COPD exacerbations with acute or acute-on-chronic respiratory acidosis (pH < 7.35 and PaCO2 > 45 mmHg). In alert, cooperative patients, NIV reduces intubation rates, hospital length of stay, and in-hospital mortality.
8A 39-year-old male non-smoker presents with exertional breathlessness. High-resolution chest CT reveals extensive panacinar emphysematous destruction with marked predilection for the bilateral lower lung zones. Spirometry shows FEV1 of 46% predicted. His serum alpha-1 antitrypsin (AAT) level is measured at 24 mg/dL (reference range 90-200 mg/dL). Which diagnostic test provides the definitive genetic confirmation of alpha-1 antitrypsin deficiency?
A.AAT phenotyping (isoelectric focusing) or direct SERPINA1 gene sequencing
B.Sweat chloride iontophoresis testing followed by CFTR gene panel
C.Measurement of circulating neutrophil elastase activity in peripheral blood
D.Immunohistochemical staining for elastase-alpha-1 antitrypsin complexes on lung biopsy
Explanation: Alpha-1 antitrypsin deficiency (AATD) is definitively diagnosed through quantitative serum AAT levels combined with qualitative phenotyping via isoelectric focusing (to identify PiMM, PiMZ, PiSZ, or PiZZ variants) and/or direct targeted genotyping/sequencing of the SERPINA1 gene on chromosome 14.
9A 62-year-old male former smoker with very severe COPD (post-bronchodilator FEV1 24% predicted, RV 210% predicted, TLC 135% predicted) has debilitating dyspnea despite maximal triple inhaler therapy and pulmonary rehabilitation. High-resolution CT shows severe, heterogeneous, upper-lobe predominant emphysema. In evaluating the patient for bronchoscopic lung volume reduction with one-way endobronchial valves (EBV), which anatomical finding is an absolute contraindication to the procedure?
A.High baseline residual volume exceeding 200% predicted
B.Absence of interlobar fissure integrity and presence of collateral ventilation
C.Upper-lobe distribution of emphysematous tissue destruction
D.DLCO between 25% and 40% of predicted normal values
Explanation: Endobronchial valve placement requires complete or near-complete interlobar fissure integrity (typically > 95% on HRCT) and documented absence of collateral ventilation (assessed via the Chartis catheter system). If collateral ventilation exists through incomplete fissures, airflow enters the target lobe from adjacent lobes, preventing atelectasis and clinical benefit.
10A 59-year-old male with severe COPD (FEV1 38% predicted) and a chronic productive cough fulfilling criteria for chronic bronchitis continues to experience frequent exacerbations (3 in the past year) despite adherent triple therapy (ICS/LABA/LAMA). He is a former smoker. His blood eosinophils are 120 cells/uL. Which oral agent targeting phosphodiesterase-4 (PDE-4) is approved to reduce exacerbations in this clinical setting?
A.Apremilast 30 mg twice daily
B.Sildenafil 20 mg three times daily
C.Theophylline 300 mg twice daily
D.Roflumilast 500 mcg once daily
Explanation: Roflumilast is an oral, selective phosphodiesterase-4 (PDE-4) inhibitor indicated as an add-on therapy to reduce the risk of exacerbations in patients with severe COPD (FEV1 < 50% predicted), chronic bronchitis, and a history of recurrent exacerbations despite optimal inhaled maintenance therapy.

About the CNN Neumología Exam

Independent study practice by OpenExamPrep for the first-time certification exam in Adult Pulmonology (Neumología Adultos) of the Consejo Nacional de Neumología, A.C. (CNN), a CONACEM-recognized specialty council. The 2026-2027 convocatoria is open from 15 September to 15 December 2026, and the digital exam is on Saturday 6 February 2027 at regional sites using the candidate's own laptop. This bank is an independent English-language MCQ study adaptation built on international guidelines (GOLD, GINA, ATS/ERS, ESC/ERS, WHO) and the Mexican TB standard NOM-006-SSA2-2013; it is not an official translation or simulation of the Spanish-language CNN exam and does not cover pediatric pulmonology.

Exam sponsor: Consejo Nacional de Neumología, A.C. (CNN). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The CNN first-time certification for adult pulmonology is a single digital theoretical exam taken on a secure platform using the candidate's own laptop at the chosen regional site (Mexico City, Monterrey or Guadalajara). The 2027 exam is on Saturday 6 February 2027, with results communicated privately by 19 February 2027. The council does not publish an item count, time limit, pass mark or topic weights.

Time Limit

Not published

Passing Score

not-published

Exam / Certification Fees

MXN 6,000 (2026-2027 convocatoria)

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Official sources

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

Weight not published

Enfermedades Obstructivas de la Vía Aérea

COPD GOLD assessment (post-bronchodilator spirometry, ABE staging, blood eosinophil thresholds for triple therapy, exacerbation treatment, long-term oxygen indications), asthma GINA strategy (MART regimens, biological agents targeting IgE, IL-5, IL-4R, severe acute asthma resuscitation), bronchiectasis diagnosis and macrolide suppression, and adult cystic fibrosis

Weight not published

Enfermedad Pulmonar Intersticial y Trastornos Inmunológicos

Idiopathic pulmonary fibrosis (HRCT UIP pattern, antifibrotic therapy with pirfenidone and nintedanib), hypersensitivity pneumonitis (exposure epidemiology in Mexico including pet birds and biomass, HRCT three-density pattern, antigen remediation), sarcoidosis (Scadding radiographic classification, organ-specific corticosteroid indications), and connective tissue disease-associated ILD (systemic sclerosis, rheumatoid arthritis)

Weight not published

Infecciones Respiratorias y Tuberculosis Pulmonar

Pulmonary tuberculosis diagnosis (GeneXpert MTB/RIF, acid-fast bacilli smear, mycobacterial culture), primary drug-susceptible regimen (2HRZE/4HR; NOM-006-SSA2-2013 105-dose primary shortened regimen), hepatotoxicity management, multidrug-resistant tuberculosis (MDR-TB and BPaL/M regimens), community-acquired pneumonia (CURB-65, empirical coverage), and endemic fungal pneumonias (histoplasmosis and coccidioidomycosis in Mexico)

Weight not published

Circulación Pulmonar y Patología Pleural

Pulmonary arterial hypertension (ESC/ERS hemodynamic definitions, precapillary criteria, vasoreactivity testing, dual oral combination therapy, parenteral prostacyclins), acute pulmonary thromboembolism (risk stratification, indications for systemic thrombolysis, DOACs), and pleural diseases (Light's criteria, complicated parapneumonic effusion, tube thoracostomy, intrapleural tPA/DNase, malignant pleural effusion)

Weight not published

Trastornos Respiratorios del Sueño y Oncología Torácica

Obstructive sleep apnea (polysomnography, apnea-hypopnea index AHI criteria, CPAP titration), obesity hypoventilation syndrome (awake daytime hypercapnia, non-invasive positive pressure ventilation), solitary pulmonary nodule management (Fleischner 2017 guidelines), and non-small cell lung cancer (TNM staging, targetable genomic alterations: EGFR, ALK, ROS1, and PD-L1 checkpoint inhibitors)

Preparing for the CNN Neumología Exam

What You Need to Know

  • Passing score: not-published
  • Assessment: The CNN first-time certification for adult pulmonology is a single digital theoretical exam taken on a secure platform using the candidate's own laptop at the chosen regional site (Mexico City, Monterrey or Guadalajara). The 2027 exam is on Saturday 6 February 2027, with results communicated privately by 19 February 2027. The council does not publish an item count, time limit, pass mark or topic weights.
  • Time limit: Not published
  • Exam / certification fees: MXN 6,000 (2026-2027 convocatoria) Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

CNN Neumología: Suggested Study Strategy

1Master the GOLD 2025-2026 reports for COPD: post-bronchodilator FEV1/FVC < 0.70, the ABE grouping, blood eosinophil thresholds for adding an inhaled corticosteroid (>= 100 cells/uL when exacerbations persist on LABA/LAMA, with the strongest benefit at >= 300), and the 5-day oral prednisone 40 mg protocol for exacerbations.
2Know the diagnostic evaluation and treatment of hypersensitivity pneumonitis in Mexico: detailed exposure history (pet birds, pigeon coops, biomass smoke), HRCT findings (centrilobular nodules, mosaic attenuation, three-density sign), bronchoalveolar lavage lymphocytosis (> 20-30%), and the paramount importance of complete antigen avoidance.
3Review tuberculosis management: the NOM-006-SSA2-2013 primary shortened regimen (60 daily HRZE doses then 45 thrice-weekly HR doses), WHO rapid molecular testing (Xpert MTB/RIF Ultra), ATS/CDC/IDSA thresholds for stopping hepatotoxic drugs (ALT > 5x ULN, or > 3x with symptoms or jaundice), and WHO BPaLM/BPaL regimens for MDR/RR-TB.
4Consolidate pulmonary arterial hypertension (PAH) hemodynamics per 2022 ESC/ERS criteria: mean PAP > 20 mmHg, PAWP <= 15 mmHg, and PVR > 2 Wood units; know vasoreactivity testing criteria (drop >= 10 mmHg to <= 40 mmHg with stable/increased CO) and risk-stratified upfront oral combination therapy (ERA + PDE-5i).
5Understand pleural effusion management using Light's criteria (exudative thresholds: pleural/serum protein > 0.5, pleural/serum LDH > 0.6, or pleural LDH > 2/3 upper limit of normal); recognize indications for prompt chest tube thoracostomy in complicated parapneumonic effusions (pH < 7.20, glucose < 40-60 mg/dL, positive Gram stain/culture, or gross pus).

Frequently Asked Questions

What is the Consejo Nacional de Neumología certification exam?

It is the first-time board certification exam of the Consejo Nacional de Neumología, A.C. (CNN), one of the specialty councils recognized by CONACEM. The council certifies both adult pulmonology (Neumología Adultos) and pediatric pulmonology; first-time certification is obtained by examination.

When is the exam held and how is it administered?

For the 2026-2027 cycle, the exam is on Saturday 6 February 2027 on a digital platform at the candidate's chosen site in Mexico City, Monterrey or Guadalajara, and candidates must bring their own laptop. Instructions are sent one week before the exam, and results are communicated privately by 19 February 2027.

What are the registration window, requirements and fee?

The convocatoria runs from 15 September to 15 December 2026 with no extension. Final-year residents who entered through CIFRHS/ENARM, graduated specialists, and foreign-trained specialists with SEP revalidation may apply by completing their electronic file on SIGME and paying the MXN 6,000 fee by transfer or deposit (no cash).

What topics should I study?

The CNN does not publish topic weights. This practice bank covers obstructive airway disease, interstitial lung disease, respiratory infections and tuberculosis (including Mexico's NOM-006-SSA2-2013 regimen), pulmonary circulation and pleural disease, and sleep medicine and thoracic oncology, using current international guidelines.

Why is this practice bank in English, and does it cover pediatric pulmonology?

The CNN exam is conducted in Spanish. This OpenExamPrep bank is an independent English-language MCQ study adaptation for adult pulmonology; it is not an official translation or simulation of the CNN exam and does not cover the separate pediatric pulmonology certification.